Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?

Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy

(2015) K. A. Ahmed et al.   ANNALS OF ONCOLOGY

Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment

(2015) Ana P. Kiess et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases

(2015) Zachary A. Kohutek et al.   JOURNAL OF NEURO-ONCOLOGY

Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors

(2015) Penny K. Sneed et al.   JOURNAL OF NEUROSURGERY

Focal or combined modality for the management of brain metastasis: did high tech radiotherapy superseded drug-radiotherapy combination?

(2014) E. Deutsch et al.   ANNALS OF ONCOLOGY

Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma

(2013) Christopher J. Anker et al.   JOURNAL OF CLINICAL ONCOLOGY

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

Outcome predictors of Gamma Knife surgery for melanoma brain metastases

(2010) Donald N. Liew et al.   JOURNAL OF NEUROSURGERY